

CONTENTS

1. Introduction	1
1.1 Introduction	1
1.2 Hypothesis	6
1.3 Aim and Objectives	6
1.4 Plan of work	6
1.5 References	6
2. Literature review	9
2.1 Anatomy and Physiology of Human Lungs	9
2.1.1 Anatomy of Lungs	9
2.1.1.1 Airways	9
2.1.1.2 Tracheobronchial Tree	9
2.1.1.3 Bronchial and Pulmonary Circulation	11
2.1.1.4 Mechanics of Respiration	11
2.1.1.5 Muscles of Respiration	11
2.1.1.5.1 Primary	11
2.1.1.5.2 Accessory	12
2.1.1.6 Mechanics of Lung Function	12
2.1.2 Physiology of Respiration	12
2.1.2.1 Lung Volumes and Capacities	12
2.1.2.2 Pulmonary Gas Exchange	13
2.2 Cancer	14
2.2.1 Types of Cancer	16
2.2.2 Cancer Statistics	18
2.2.3 Risk factors and Causes of Cancer	20
2.3 Lung Cancer	22
2.3.1 Causes and Risk factors of lung cancer	23
2.3.1.1 Smoking	23
2.3.1.2 Passive smoking	23
2.3.1.3 Exposure to asbestos fibers	24
2.3.1.4 Exposure to radon gas	24
2.3.1.5 Familial predisposition	24
2.3.1.6 Lung diseases	25

2.3.1.7 Prior history of lung cancer	25
2.3.1.8 Air pollution	25
2.3.1.9 Exposure to diesel exhaust	25
2.3.2 Types of Lung Cancer	25
2.3.3 Treatment options for NSCLC	28
2.3.3.1 Surgery	28
2.3.3.2 Chemotherapy and Radiation	29
2.3.3.3 Chemotherapy before Other Treatments (Neoadjuvant Treatment)	29
2.3.3.4 Targeted Treatments	30
2.3.3.5 Immunotherapy	31
2.3.4 Novel drug delivery systems for the treatment of NSCLC	33
2.3.4.1 Polymeric Nanoparticles	33
2.3.4.2 Polymeric micelles	34
2.3.4.3 Dendrimers	35
2.3.4.4 Liposomes	35
2.3.4.5 Viral Nanoparticles	36
2.3.4.6 Carbon Nanotubes	37
2.3.5 Passive Targeting	37
2.3.6 Active Targeting	38
2.3.7 Long circulating of Novel carriers	38
2.3.8 Previous work done on NSCLC drugs	39
2.3.8.1 Docetaxel	39
2.3.8.2 Gemcitabine	40
2.3.8.3 Paclitaxel	40
2.3.8.4 Vinorelbine	40
2.3.8.5 Pemetrexed	41
2.4 Spherulites: A Novel vesicular drug Delivery System for Tumour Targeting	41
2.4.1 Characteristics of Spherulites	41
2.4.2 Preparation of Spherulites	42
2.4.3 Previous work done on Spherulites	42
2.5 Drug Profile	43
2.5.1 Gemcitabine Hydrochloride	43
2.5.1.1 Mechanism of Action	44

2.5.1.2 Pharmacokinetics	44
2.5.1.3 Indications and Usage	44
2.5.1.4 Adverse reactions	45
2.5.1.5 Problems associated with Gemcitabine hydrochloride	45
2.5.2 Vinorelbine Tartrate	46
2.5.2.1 Mechanism of Action	46
2.5.2.2 Pharmacokinetics	47
2.5.2.3 Indications and Usage	47
2.5.2.4 Adverse reactions	47
2.5.2.5 Problems associated with Vinorelbine Tartrate	48
2.6 Excipient Profile	48
2.6.1 Soyabean Phosphatidylcholine	48
2.6.2 1,2-distearoyl- sn- glycerol - 3- phosphoethanolamine -N -[amino (polyethyleneglycol)-2000] (DSPE PEG 2000)	49
2.6.3 Cholesterol	49
2.6.4 Potassium oleate	50
2.6.5 Mannitol	51
2.7 References	52
3. Analytical methods	59
3.1 Introduction	59
3.2 Materials and Equipment	60
3.2.1 Materials	60
3.2.2 Equipments	60
3.3 Methods	60
3.3.1 Analytical Methods for estimation of Gemcitabine hydrochloride	60
3.3.1.1 UV-Visible Spectrophotometric Method in Distilled Water	60
3.3.1.2 UV-Visible Spectrophotometric Method in Phosphate-buffered Saline (PBS) pH 7.4	61
3.3.1.3 Method Validation	62
3.3.1.3.1 Linearity	62
3.3.1.3.2 Accuracy	62
3.3.1.3.3 Precision	62
3.3.1.3.4 Limit of detection (LOD) and Limit of quantification (LOQ)	62

3.3.1.4 Analytical Interference study	62
3.3.1.5 Estimation of Gemcitabine Hydrochloride using LCMS-MS method	63
3.3.1.6 Method Validation	65
3.3.1.6.1 Linearity	65
3.3.1.6.2 Accuracy	65
3.3.1.6.3 LOQ	65
3.3.2 Analytical Methods for estimation of Vinorelbine Tartrate	65
3.3.2.1 UV-Visible Spectrophotometric Method in Distilled Water	65
3.3.2.2 UV-Visible Spectrophotometric Method in Phosphate-buffered Saline (PBS) pH 7.4	66
3.3.2.3 Method Validation	66
3.3.2.4 Analytical Interference study	67
3.3.2.5 Estimation of Vinorelbine Tartrate using LCMS-MS method	67
3.3.2.6 Method Validation	69
3.4 Results and Discussion	69
3.4.1 Analytical method for estimation of Gemcitabine Hydrochloride	69
3.4.1.1 UV-Visible Spectrophotometric Method for estimation of Gemcitabine Hydrochloride in Distilled Water	69
3.4.1.2 UV-Visible Spectrophotometric Method for estimation of Gemcitabine Hydrochloride in PBS pH 7.4	71
3.4.1.3 Method Validation	73
3.4.1.3.1 Accuracy	73
3.4.1.3.2 Precision	74
3.4.1.3.3 LOD and LOQ	74
3.4.1.4 Analytical Interference Study	74
3.4.1.5 Estimation of Gemcitabine Hydrochloride using LCMS-MS method	75
3.4.1.5.1 Calibration plot of Gemcitabine Hydrochloride in rat plasma	75
3.4.1.5.2 Calibration plot of Gemcitabine Hydrochloride in Heart homogenate	78
3.4.1.5.3 Calibration plot of Gemcitabine Hydrochloride in Lungs homogenate	79

3.4.1.5.4 Calibration plot of Gemcitabine Hydrochloride in Liver homogenate	80
3.4.1.5.5 Calibration plot of Gemcitabine Hydrochloride in Kidney homogenate	82
3.4.1.5.6 Calibration plot of Gemcitabine Hydrochloride in Spleen homogenate	83
3.4.2 Analytical method for estimation of Vinorelbine Tartrate	85
3.4.2.1 UV-Visible Spectrophotometric Method for estimation of Vinorelbine Tartrate in Distilled Water	85
3.4.2.2 UV-Visible Spectrophotometric Method for estimation of Vinorelbine Tartrate in PBS pH 7.4	87
3.4.2.3 Method Validation	89
3.4.2.3.1 Accuracy	89
3.4.2.3.2 Precision	90
3.4.2.3.3 LOD and LOQ	90
3.4.2.4 Analytical Interference Study	90
3.4.2.5 Estimation of Vinorelbine tartrate using LCMS-MS method	91
3.4.2.5.1 Calibration plot of Vinorelbine tartrate in rat plasma	91
3.4.2.5.2 Calibration plot of Vinorelbine tartrate in Heart homogenate	94
3.4.2.5.3 Calibration plot of Vinorelbine tartrate in Lungs homogenate	95
3.4.2.5.4 Calibration plot of Vinorelbine tartrate in Liver homogenate	97
3.4.2.5.5 Calibration plot of Vinorelbine tartrate in Kidney homogenate	98
3.4.2.5.6 Calibration plot of Vinorelbine tartrate in Spleen homogenate	99
3.5 References	101
4. Preformulation studies and Preliminary Optimization	103
4.1 Introduction	103
4.2 Materials and Equipment	104
4.2.1 Materials	104

4.2.2 Equipments	104
4.3 Preformulation studies	104
4.3.1 Methods	104
4.3.2 Results and Discussion	105
4.3.2.1 Results of preformulation study of GCH	105
4.3.2.2 Results of preformulation study of VLB	109
4.4 Preliminary Optimization	112
4.4.1 Preliminary Optimization of formulation variables	113
4.4.1.1 Screening of Lipids	113
4.4.1.2 SPC concentration	114
4.4.1.3 SPC:Cholesterol ratio	114
4.4.1.4 SPC:DSPE-PEG 2000 ratio (mol %)	115
4.4.2 Preliminary Optimization of process variables	116
4.4.2.1 Hydration time	116
4.4.2.2 Type of Homogenization assembly	116
4.4.2.3 Homogenization time and speed	118
4.4.2.4 Extrusion	119
4.5 References	120
5. Formulation Development	123
5.1 Introduction	123
5.2 Materials and Equipment	124
5.2.1 Materials	124
5.2.2 Equipments	124
5.3 Preparation and Optimization of GCH loaded Spherulites	125
5.3.1 Preparation of spherulites formulation and optimization by Design of Experiment®	125
5.3.1.1 Determination of Spherulites size	126
5.3.1.2 Determination of % Entrapment Efficiency (% EE)	127
5.3.1.3 Checkpoint analysis	129
5.3.2 Results and Discussion for Formulation and Optimization of GCH loaded Spherulites	129
5.3.2.1 Statistical evaluation of results of spherulites size	129

5.3.2.2 Statistical evaluation of results of % EE	131
5.3.2.3 Results of Checkpoint Analysis	134
5.4 Preparation and Optimization of VLB loaded Spherulites	135
5.4.1 Preparation of spherulites formulation and optimization by Design of Experiment®	135
5.4.1.1 Determination of spherulites size	137
5.4.1.2 Determination of % Entrapment efficiency (% EE)	137
5.4.1.3 Checkpoint analysis	139
5.4.2 Results and Discussion for Formulation and Optimization of VLB loaded Spherulites	139
5.4.2.1 Statistical evaluation of results of spherulites size	139
5.4.2.2 Statistical evaluation of results of %EE	142
5.4.2.3 Results of Checkpoint Analysis	145
5.5 References	146
6. Characterization of Formulations	148
6.1 Introduction	148
6.2 Materials and Equipment	148
6.2.1 Materials	148
6.2.2 Equipments	148
6.3 Methods	149
6.3.1 Spherulites size and Zeta (ζ) potential	149
6.3.2 % Entrapment efficiency (% EE) and % Drug loading (% w/w)	149
6.3.3 Morphological analysis by SEM and TEM	149
6.3.3.1 SEM analysis	149
6.3.3.2 TEM analysis	150
6.3.4 <i>In Vitro</i> drug release study	150
6.3.5 Determination of Osmolality	150
6.3.6 Electrolyte-induced flocculation study	151
6.4 Results and discussion	151
6.4.1 GCH loaded Non-PEGylated and PEGylated Spherulites	151
6.4.1.1 Spherulites size and Zeta (ζ) potential	151
6.4.1.2 Entrapment efficiency (%EE) and % Drug loading (%w/w)	153
6.4.1.3 Morphological analysis by SEM and TEM	154

6.4.1.4 <i>In Vitro</i> drug release study	157
6.4.1.5 Determination of Osmolality	159
6.4.1.6 Electrolyte-induced flocculation study	159
6.4.2 VLB loaded Non-PEGylated and PEGylated Spherulites	160
6.4.2.1 Spherulites size and Zeta (ζ) potential	160
6.4.2.2 Entrapment efficiency (%EE) and % Drug loading (%w/w)	163
6.4.2.3 Morphological analysis by SEM and TEM	164
6.4.2.4 <i>In Vitro</i> drug release study	166
6.4.2.5 Determination of Osmolality	168
6.4.2.6 Electrolyte-induced flocculation study	168
6.5 References	170
7. <i>In vitro</i> cytotoxicity study	172
7.1 Introduction	172
7.1.1 Cytotoxicity study by MTT Assay	172
7.1.2 Cell Cycle analysis and Apoptosis study	172
7.2 Materials and Equipment	173
7.2.1 Cell Line	173
7.2.2 Materials	174
7.2.3 Equipments	174
7.3 Methods	174
7.3.1 Cell Cytotoxicity study by MTT Assay	174
7.3.2 Apoptosis study and Cell cycle analysis by FACS	175
7.4 Results and Discussion	175
7.4.1 Results of MTT Assay	175
7.4.2 Results of Apoptosis study and Cell Cycle Analysis	183
7.5 References	189
8. <i>In vivo</i> studies	192
8.1 Introduction	192
8.1.1 Acute toxicity study	192
8.1.2 <i>In vivo</i> Pharmacokinetic study	192
8.1.3 <i>In vivo</i> Biodistribution study	193
8.2 Materials and Equipments	193
8.2.1 Materials	193

8.2.2 Equipments	194
8.3 Methods	194
8.3.1 Institutional Animals Ethics Committee (IAEC) approval	194
8.3.2 Hemocompatibility Study	194
8.3.3 Acute Toxicity Study	195
8.3.4 <i>In vivo</i> Pharmacokinetic study	195
8.3.5 <i>In vivo</i> Biodistribution study by LCMS-MS analysis	196
8.3.6 <i>In vivo</i> Biodistribution study of GCH and GCH loaded formulations by Gamma (γ) scintigraphy	197
8.3.6.1 Radiolabelling of GCH with Technetium-99m (^{99m}Tc)	197
8.3.6.2 Quality Control of ^{99m}Tc -labelled GCH	197
8.3.6.3 Radio-complex stability	197
8.3.6.4 Transchelation Study (DTPA Challenge)	198
8.3.6.5 Biodistribution studies in Rats	198
8.3.7 <i>In vivo</i> Biodistribution study of VLB and VLB loaded formulations by Gamma (γ) scintigraphy	199
8.3.7.1 Radiolabelling of VLB with ^{99m}Tc	199
8.3.7.2 Quality Control of ^{99m}Tc -labelled VLB	199
8.3.7.3 Radio-complex stability	199
8.3.7.4 Transchelation Study (DTPA Challenge)	199
8.3.7.5 Biodistribution studies in Rats	200
8.4 Results and Discussion	201
8.4.1 Hemocompatibility Study	201
8.4.2 Acute Toxicity Study	202
8.4.3 <i>In vivo</i> Pharmacokinetic study	203
8.4.4 <i>In vivo</i> Biodistribution study by LCMS-MS analysis	206
8.4.5 <i>In vivo</i> Biodistribution study of GCH and GCH loaded formulations by Gamma (γ) scintigraphy	215
8.4.5.1 Radiolabelling, Quality Control, and stability of ^{99m}Tc -GCH	215
8.4.5.2 Transchelation Study (DTPA Challenge)	216
8.4.5.3 <i>In vivo</i> Biodistribution studies in Rats	217
8.4.6 <i>In vivo</i> Biodistribution study of VLB and VLB loaded formulations by Gamma (γ) scintigraphy	222

8.4.6.1 Radiolabelling, Quality Control, and stability of ^{99m} Tc-VLB	222
8.4.6.2 Transchelation Study (DTPA Challenge)	223
8.4.6.3 <i>In vivo</i> Biodistribution studies in Rats	224
8.5 References	230
9. Stability Studies	232
9.1 Introduction	232
9.2 Materials and Equipments	232
9.2.1 Materials	232
9.2.2 Equipments	233
9.3 Method	233
9.4 Results and Discussion	233
9.4.1 Stability study of GCH loaded Non-PEGylated spherulites	233
9.4.2 Stability study of GCH loaded PEGylated spherulites	235
9.4.3 Stability study of VLB loaded Non-PEGylated spherulites	237
9.4.4 Stability study of VLB loaded PEGylated spherulites	238
9.5 References	240
10. Summary and Conclusion	241
10.1 Summary	241
10.2 Conclusion	251